REFERENCES
- Doran CM. New approaches to using antiretroviral therapy for the management of HIV infection. Ann Pharmacother. 1997;31:228–236.
- Hammer SM. Advances in antiretroviral therapy and viral load monitoring. AIDS. 1996;10\(suppl 3):S1—S11.
- Hendriks JCM, Satten GA, Longini IM, et al. Use of immu-nological markers and continuous-time Markov models to estimate progression of HIV infection in homosexual men. AIDS. 1996;10:649–656.
- Longini IM, Clark WS, Byers RH, et al. Statistical analysis of the stages of HIV infection using a Markov model. Stat Med. 1989;8:831–843.
- Longini IM, Clark WS, Karon JM. Effect of routine use of therapy in slowing the clinical course of human immunode-ficiency virus (HIV) infection in a population-based cohort. Am J Epidemiol. 1993;137(11):1229–1239.
- Longini IM, Clark WS, Gardner LI, Brundage JF. The dy-namics of CD4+ T-lymphocyte decline in HIV-infected indi-viduals: A Markov modeling approach. J Acquir Immune Defic Syndr. 1991;4(11):1141–1147.
- Chiang CL. An Introduction to Stochastic Processes and Their Applications. New York: Krieger; 1980.
- Mellors WM, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic marker of HIV-1 infection. Ann Intern Med. 1997;126:946–954.
- O'Brien TR, Blattner WA, Waters D, Eyster ME, Hilgartner MW, Cohen AR. Serum HIV-RNA levels and time to devel-opment of AIDS in the multicenter hemophilia cohort study. JAMA.1996;276(2):105–110.
- Phillips AN, Eron JJ, Bartlett JA, et al. HIV-1 RNA levels and the development of clinical disease. A/DS.1996;10:859–865.
- Phillips AN, Eron JJ, Bartlett JA, et al. Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals. A/DS.1997; 11:169–175.
- Hammer SM. Advances in antiretroviral therapy and viral load monitoring. AIDS.1996;10(suppl 3):S1—S11.
- Mission SIDA. Soins et Sida, les chiffres cies. Ministere de l'Emploi et de la Solidarité, 6'me edition, janvier 1998.
- Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. A/DS.1997;11:F101—F105.
- Keiser P, Kvanli M, Turner D, et al. Decreased hospital utilization and costs are associated with protease inhibitor therapy but not with nucleoside therapy. In: Program and abstracts of the Fifth Conference on Retroviruses and Op-portunistic Infections; February 1–5, 1998; Chicago, Illi-nois. Abstract 204.
- Palella F, Moorman A, Chmiel J, et al. Continued decline in morbidity and mortality among patients with advanced HIV infection receiving highly active antiretroviral therapy (HAART). In: Program and abstracts of the Sixth Confer-ence on Retroviruses and Opportunistic Infections; Janu-ary 31—February 4, 1999; Chicago, Illinois. Abstract 689.